Skip to main content
ABVX logo

Abivax S.A. (ABVX) Stock: Price, Forecast & Analyst Target

Abivax S.A. (ABVX) — MoonshotScore 53/100 (Fair band), calculated Nov 18, 2026. Price $73.20 (-9.24%), as of the Nov 20, 2026 trading session; market cap $6.41B. Expected results Dec 21, 2026.

Educational signal · not a buy or sell recommendation · How to read this

$73.20 −$7.45 (-9.24%) Market Cap $6.41B

Abivax S.A. · ABVX · NASDAQ · Healthcare · Biotechnology

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases.

Price as of Nov 20, 2026

Key Statistics

53 of 100

MoonshotScore v2 · Abivax (ABVX)

Fair
Business Quality Solid (68)
Financial Safety Fortress (85)
Valuation Full (49)
Growth Durability Shrinking (15)
Momentum Quiet (43)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and a strong balance sheet, but stalling growth and a full valuation. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Solid; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Quiet.

  • quarterly revenue €0 (Q2 FY2026, quarter ended Jun 2026)
  • EPS beat 0 of the last 4 reports
  • Altman Z 36.47 · Piotroski F 3

Holding back: soft growth

Helping: business quality, balance-sheet strength

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ABVX (53 recorded, newest six shown)
RecordedScoreBand
59Fair
52Fair
52Fair
53Fair
53Fair
53Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$73.20
Change on the day-9.24%
52-week range$69.81–$148.83
Market capitalisation$6.41B—
Shares traded on the day14.82M
Beta (volatility vs the S&P 500)-0.25

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $73, high $145, latest $73. 4 reported quarters marked, 2 above and 2 below the recorded estimate. $145 $73 high $145 Dec 15, 2025 · Earnings results · reported below the recorded estimate · close $1261Mar 23, 2026 · Earnings results · reported above the recorded estimate · close $1202May 22, 2026 · Earnings results · reported above the recorded estimate · close $1223Sep 21, 2026 · Earnings results · reported below the recorded estimate · close $1054 Oct 17, 2025 Nov 20, 2026 · $73 $93Oct 17, 2025$102Oct 31, 2025$110Nov 14, 2025$125Nov 28, 2025$126Dec 12, 2025$142Dec 26, 2025$114Jan 9, 2026$122Jan 23, 2026$118Feb 6, 2026$130Feb 20, 2026$109Mar 6, 2026$120Mar 20, 2026$118Apr 2, 2026$120Apr 17, 2026$118May 1, 2026$115May 15, 2026$133May 29, 2026$97Jun 12, 2026$98Jun 26, 2026$140Jul 10, 2026$126Jul 24, 2026$131Aug 7, 2026$115Aug 21, 2026$115Sep 4, 2026$105Sep 18, 2026$93Oct 2, 2026$88Oct 16, 2026$87Oct 30, 2026$88Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Abivax (ABVX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Strong
Valuation Neutral
Growth Durability Negative
Momentum Neutral

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Abivax (ABVX), and what does it report?

Short answer

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. Abivax S.A. (ABVX) is listed on NASDAQ. Abivax S.A. (ABVX) is classified as Healthcare / Biotechnology. SEC filing business address: 7 BD Haussmann, Paris. It employs 98 people and is led by Marc de Garidel. In Q2 FY2026 it reported revenue of €0 and net income of -€117M. The market values it at $6.41B.

2 · Latest results

What do the latest results show for Abivax (ABVX)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of €0. Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$1.37M Sep 21, 2026
Latest report · revenue estimate
$799,166 Sep 21, 2026
Latest report · revenue vs estimate
Above estimate Sep 21, 2026
Latest report · EPS vs estimate
Below estimate Sep 21, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Sep 21, 2026$1.37M$799,166−$1.7100−$0.9755
May 22, 2026$1.51M$401,125−$0.7100−$1.0700
Mar 23, 2026$515,064$1.80M−$1.1900−$1.7000
Dec 15, 2025$2.40M$1.35M−$2.4717−$0.7865
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026€0-€117M-€1.47 (diluted)
Q4 FY2025€0-€288M-€4.14 (diluted)
Q2 FY2025€0-€48M-€0.76 (diluted)
Q4 FY2024€0-€52M-€0.83 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Abivax (ABVX)?

Short answer

The MoonshotScore pillars rate business quality, balance-sheet strength as strengths. What is holding it back is soft growth. The distress and quality screens read Altman Z 36.47 · Piotroski F 3. Trailing ratios: ROA -57.5% · current ratio 8.75 · earnings yield -4.3% · free-cash-flow yield -1.8%.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 1 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Abivax (ABVX)?

Short answer · as of

The next earnings report is expected on Dec 21, 2026. Current published price targets run low $118.00 · high $180.00 · consensus $156.00 · median $156.50 against a quoted price of $73.20 (as of Nov 20, 2026).

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Abivax compare with its peers?

Short answer

Abivax's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.89 Nov 20, 2026$7.38B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$308.89 Nov 20, 2026$9.15B96 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Named competitor$63.62 Nov 20, 2026$6.96B91 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$121.40 Nov 20, 2026$7.92B88 5-pillar Nov 18, 2026
Edgewise Therapeutics, Inc. (EWTX) Same industry, near in market value$39.91 Nov 20, 2026$4.37B84 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$17.58 Nov 20, 2026$5.04B83 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$286.85 Nov 20, 2026$5.74B71 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$95.81 Nov 20, 2026$6.50B67 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Same industry, near in market value$13.61 Nov 20, 2026$4.78B67 5-pillar Nov 18, 2026
Veradermics, Incorporated (MANE) Same industry, near in market value$119.52 Nov 20, 2026$5.04B66 5-pillar Nov 18, 2026
Belite Bio, Inc. (BLTE) Same industry, near in market value$127.38 Nov 20, 2026$5.17B64 5-pillar Nov 18, 2026
Abivax (ABVX) — this page$73.20$6.41B53
Jazz Pharmaceuticals plc (JAZZ) Named competitor$236.45 Nov 19, 2026$15.2B40 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$118.00 – $180.00
Consensus target
$156.00
Median target
$156.50

Consensus record · Captured .

Measured against a quoted price of $73.20 (as of Nov 20, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
71.7% Period end Sep 30, 2026
Previous quarter · ownership
79.1% Prior to period end Sep 30, 2026
Reporting holders
364 Period end Sep 30, 2026
Previous quarter · holders
372 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Helikon Investments Ltd4,222,896
Darwin Global Management, Ltd.4,021,583
Vestal Point Capital, LP3,960,000
Tcg Crossover Management, LLC3,663,038
Citadel Advisors LLC2,171,400

Tracked investors

Which of the 16 named investors we follow held ABVX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ABVX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Abivax (ABVX)?

Read these with our analysis →

Abivax Healthcare Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the ABVX research dossier (written Jun 13, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ABVX?

ABVX carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is ABVX a good stock to buy?

Stock Expert AI does not rate ABVX buy, sell or hold. Abivax S.A. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ABVX stock price today?

The last price recorded for Abivax S.A. (ABVX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ABVX price target?

The analyst consensus price target for Abivax S.A. (ABVX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for ABVX?

The primary risks for Abivax S.A. stem from the inherent uncertainties of drug development. These include the potential for clinical trial failures at any stage, which could significantly impede product development and market prospects.

What are the key factors to evaluate for ABVX?

Abivax S.A. (ABVX) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Engages in early-stage research programs for infectious diseases such as Dengue fever, influenza, and respiratory syncytial virus. Not financial advice.

How frequently does ABVX data refresh on this page?

ABVX's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ABVX's recent stock price performance?

Abivax S.A. (ABVX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ABVX overvalued or undervalued right now?

Abivax S.A. (ABVX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 52 figures on this page — 1 from SEC filings and earnings calls, 44 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.